All In MedTech

Device Trial Radar · NCT00918229

Pilot Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects

One-arm, Multi-center, International Prospective Study to Assess the Safety and Efficacy of BioProtect Biodegradable Implantable Balloon in Prostate Cancer Subjects Undergoing Radiotherapy

Last checked: Nov 19, 2026Latest source record: Nov 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Jun 2009

Primary completion

May 2011

Study completion May 2011

Sponsor

Lead sponsor
BioProtectNot on our public-company list
Sponsor type
Industry
First posted
Jun 11, 2009

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated device
Yes
Who can join
Male only, from 45 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Goal The study's primary goal is to assess the safety of the BioProtect biodegradable balloon implant and implantation procedure, in prostate cancer subjects undergoing routine radiation therapy (XRT) treatment. Safety of the BioProtect device will be assessed by reporting adverse events. Secondary Goal The study's secondary goal is to evaluate the effectiveness of the BioProtect biodegradable balloon implant in prostate cancer subjects undergoing routine XRT treatment. Effectiveness will be assessed in terms of increased distance between anterior rectal wall and prostate and noticeable reduction of isodose to the rectum.

Conditions

  • Prostate Cancer

Interventions

  • balloon implantDevice

    Absorbable perirectal spacer implantation

  • Balloon implantationProcedure

    Implantation of the balloon between the prostate and the anterior rectal wall

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Achieving a Reduction of at Least 25% of the Volume of the Rectum Receiving at Least 70 Gy.Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Virginia Commonwealth University School of Medicine, Massey Cancer Center

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.